Article
16 Jan 2026
"Deregulation" On The Menu: Big Changes For Wellness And CDS Technologies
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
09 Jan 2026
FDA Continues Crack Down On DTC Advertising: Untitled Letter Highlights Pitfalls In Schizophrenia Drug Promotion
Article
08 Dec 2025
What To Watch: Continued DTC Advertising Enforcement
Article
26 Nov 2025
Congress Joins The Biomanufacturing Onshoring Party
Article
05 Nov 2025
Texas Sues Johnson & Johnson And Kenvue Over Tylenol: Scientific Evidence, Regulatory Shifts, And The Future Of OTC Drug Labeling
Article
20 Oct 2025
What To Watch: Human Cell And Tissue Product Regulation
Article
08 Oct 2025
FDA Touts Continued Commitment To Cell And Gene Therapy Products Through Trio Of Guidances
Article
03 Oct 2025
FDA's Wave Of Untitled Letters Signals Stricter Scrutiny For DTC Pharma Ads
Article
23 Sep 2025
FDA Unleashes Wave Of Enforcement: The Industry Faces A Crackdown On Drug Advertising
Article
12 Sep 2025
FDA's Vast Ad/Promo Warning – Enforcement Ramp-Up Or PR Nothingburger?
Article
07 Aug 2025
What To Watch: WHOOP Warning Letter
Article
01 Aug 2025
DOJ False Claims "Working Group" Update
Article
03 Jul 2025
What's Going On With Human Cell And Tissue Products?
Article
23 Jun 2025
What To Watch: Potential Increase In Enforcement Of "RUO" Diagnostics
Article
16 Jun 2025
FDA Ratchets Enforcement On Social Media Promotion In New Warning Letter
Article
20 May 2025
Reflections On The FDLI 2025 Annual Conference – Differing Tones, Shared Goals
Article
14 May 2025
Onshoring Pharma Ops: Reading Recent EO And Policy Tea Leaves
Article
10 Apr 2025
LDT Final Rule Series: Part 4 – Rule Overturned By Federal District Court
Article
10 Apr 2025
LDT Final Rule Series: Part 4 – Rule Overturned By Federal District Court
Article
13 Mar 2025
Reminder: FDA Does, In Fact, Review DOF